Nonmotor symptoms of Parkinson’s disease

References

• Parkinson J. An essay on the shaking palsy. 1817. [reprint of monograph published by Sherwood, Neely, and Jones, London]. J. Neuropsychiatry Clin. Neurosci.14, 223–236 (2002).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Depression and Parkinson’s disease: a review. Am. J. Psychiatry149, 443–454 (1992).
   PubMed Web of Science ®Google Scholar
• Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin. Neuropharmacol.11(6), 512–519 (1988).
   PubMed Web of Science ®Google Scholar
• Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson’s disease – a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat. Disord.11(7), 465–468 (2005).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J. Am. Geriatr. Soc.52(5), 784–788 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology60(11), 1756–1761 (2003).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov. Disord.16(3), 507–510 (2001).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord.8(3), 193–197 (2002).
   PubMed Web of Science ®Google Scholar
• Sullivan KL, Ward CL, Hauser RA, Dunne PB, Zesiewicz TA. Prevalence and treatment of non-motor symptoms in Parkinson’s disease. Presented at: 58th American Academy of Neurology Annual meeting. San Diego, CA, USA 1–8 April P04, 031 (2006).
   Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AHV et al. An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson’s disease: The NMSQuest study. Mov. Disord. (2006) (In Press).
   Google Scholar
• Goetz CG, Fahn S, Martinez-Martin P et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov. Disord. (2006) (Epub ahead of print).
   Google Scholar
• Awerbuch GI, Sandyk R. Autonomic functions in the early stages of Parkinson’s disease. Int. J. Neurosci.64(1–4), 7–14 (1992).
   PubMed Web of Science ®Google Scholar
• Kremer HP. The hypothalamic lateral tuberal nucleus: normal anatomy and changes in neurological diseases. Prog. Brain Res.93, 249–261 (1992).
   Google Scholar
• Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associate with ganglion cell loss in achalasia. Similarity to Parkinson’s disease. Gastroenterology87, 848–856 (1984).
   PubMed Web of Science ®Google Scholar
• McTavish D, Goa KL. Midodrine: a review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs38, 757–777 (1989).
   PubMed Web of Science ®Google Scholar
• Pittner H, Stormann H, Enzenhofer R. Pharmacodynamic actions of midodrine, a new alpha-adrenergic stimulating agent, and its main metabolite, ST 1059. Arzneimittelforschung26, 2145–2154 (1976).
   PubMed Web of Science ®Google Scholar
• Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A et al. Pharmacodynamics of midodrine, an antihypotensive agent. Clin. Pharmacol. Ther.39, 586–591 (1986).
   PubMedGoogle Scholar
• Kaufman H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology38, 951–956 (1988).
   PubMedGoogle Scholar
• Jankovic J, Gilden JL, Hiner BC, Kaufman H, Brown DC. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med95, 38–48 (1993).
   PubMed Web of Science ®Google Scholar
• Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klinische Wochenschrift69, 906–909 (1991).
   PubMedGoogle Scholar
• Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology37(7), 1253–1255 (1987).
   PubMed Web of Science ®Google Scholar
• Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon? J. Neurol. Neurosurg. Psychiatry51(12), 1503–1507 (1988).
   PubMedGoogle Scholar
• Sullivan KL, Staffetti JF, Hauser RA et al. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov. Disord.21(1), 115–116 (2005).
   Google Scholar
• Liu Z, Sakakibara R, Odaka T, Uchiyama Tet al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov. Disord.20(6), 680–686 (2005).
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Shinotoh H, Uchiyama T et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton. Neurosci.92(1–2), 76–85 (2001).
   PubMed Web of Science ®Google Scholar
• Coates C, Bakheit AM. Dysphagia in Parkinson’s disease. Eur. Neurol.38(1), 49–52 (1997).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Chia LG, Hsu CY, Lin WY, Kao CH, Yeh SH. Dysphagia in Parkinson’s disease. Assessment by solid phase radionuclide scintigraphy. Clin. Nuc. Med.19, 405–407 (1994).
   Google Scholar
• Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov. Disord.21(6), 737–745 (2006).
   PubMed Web of Science ®Google Scholar
• Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinson’s disease: prevalence and associated factors. Arq. Neuropsiquiatr.61(2B), 359–363 (2003).
   PubMed Web of Science ®Google Scholar
• Vesicare® Package Insert. GlaxoSmithKline, Research Triangle Park, NC, USA.
   Google Scholar
• Enablex® Package Insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
   Google Scholar
• Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson’s disease. Urology67(3), 447–451 (2006).
   Google Scholar
• Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson’s disease patients and normal controls. Parkinsonism Relat. Disord.10(2), 67–71 (2003).
   PubMed Web of Science ®Google Scholar
• Nehra A, Moreland RB. Neurologic erectile dysfunction. Urol. Clin. North Am.28(2), 289–308 (2001).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Helal M, Hauser RA. Sildenafil Citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov. Disord.15, 305–308 (2000).
   PubMed Web of Science ®Google Scholar
• Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson’s disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism Relat. Disord.11(8), 509–512 (2005).
   PubMed Web of Science ®Google Scholar
• Vogel HP, Schiffter R. Hypersexuality – a complication of dopaminergic therapy in Parkinson’s disease. Pharmacopsychiatria16(4), 107–110 (1983).
   PubMedGoogle Scholar
• Voon V, Hassan K, Zurowski M et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology67(7), 1254–1257 (2006).
   PubMed Web of Science ®Google Scholar
• Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Relat. Disord.6, 381–386 (2005).
   Google Scholar
• Romito LM, Raja M, Daniele A et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov. Disord.17(6), 1371–1374 (2002).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Desboeuf K, Galitzky M et al. Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson’s disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur. J. Neurol.13(3), 209–214 (2006).
   PubMed Web of Science ®Google Scholar
• Dhawan V, Dhoat S, Williams AJ et al. The range and nature of sleep dysfunction in untreated Parkinson’s disease (PD). A comparative controlled clinical study using the Parkinson’s disease sleep scale and selective polysomnography. J. Neurol. Sci.248(1–2), 158–62 (2006).
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P. Clinical assessment of nocturnal disability in Parkinson’s disease: the Parkinson’s Disease Sleep Scale. Neurology63(8 Suppl. 3), S17–S20 (2004).
   Google Scholar
• Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson’s disease. J. Clin. Psychiatry67(6), 958–963 (2006).
   PubMed Web of Science ®Google Scholar
• Gomez-Esteban JC, Zarranz JJ, Lezcano E et al. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson’s disease. Mov. Disord.21(7), 983–988 (2006).
   PubMed Web of Science ®Google Scholar
• Juri C, Chana P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin. Neuropharmacol.28(4), 185–187 (2005).
   PubMedGoogle Scholar
• Homan CN, Wenzyl K, Suppan M et al. Sleep attacks after acute administration of apomorphine. Mov. Disord.15(Suppl. 3), 108 (2000).
   Google Scholar
• Arnulf I, Bonnett AM, Damier P et al. Hallucinations, REM sleep, and Parkinson’s disease. Neurology55, 281–288 (2000).
   PubMed Web of Science ®Google Scholar
• Hobson DE, Lang AE, Martin WR et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson’s disease. A survey by the Canadian Movement Disorders Group. JAMA287, 455–463 (2002).
   PubMed Web of Science ®Google Scholar
• Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology67(5), 853–888 (2006).
   PubMed Web of Science ®Google Scholar
• Shpirer I, Miniovitz A, Klein C et al. Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomnography study. Mov. Disord.9, 1432–1438 (2006).
   Google Scholar
• Ondo WG, Dat Vuon G, Khan H et al. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology57, 1392–1396 (2001).
   PubMed Web of Science ®Google Scholar
• Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med. J.41, 167–184 (2000).
   PubMed Web of Science ®Google Scholar
• Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease: a meta-analysis of randomized controlled trials. Drug Saf.24(11), 863–868 (2001).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease. A randomized controlled trial. JAMA284, 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Hogl B, Saletu M, Brandauer E et al. Modafinil for the treatment of daytime Sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep25(8), 905–909 (2002).
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG et al. Randomized trial of modafinil for treating subjective daytime Sleepiness in patients with Parkinson’s disease. Mov. Disord.18(3), 287–293 (2003).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov. Disord.15, 1269–1271 (2000).
   Google Scholar
• Frucht S, Rogers JD, Green PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52, 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev.9(3), 185–200 (2005).
   PubMed Web of Science ®Google Scholar
• Brodsky MA, Godbold J, Olanow CW. sleepiness in Parkinson’s diseasea. Parkinsonism Relat. Disord.7, S93 (2001).
   Google Scholar
• Olanow CW, Schapria AH, Roth T. Waking up to sleep episodes in Parkinson’s disease. Mov. Disord.15(2), 212–215 (2000).
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Desboeuf K, Galitzky M et al. Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson’s disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur. J. Neurol.13(3), 209–214 (2006).
   PubMed Web of Science ®Google Scholar
• Homann CN, Wenzel K, Suppan K et al. Sleep attacks in patients taking dopamine agonists: review. Br. Med. J.324, 1483–1487 (2002).
   PubMed Web of Science ®Google Scholar
• Frucht S, Roger JD, Green PE et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52, 1908–1910 (1999).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Gauger L, McDowell Andersen W, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov. Disord.15(4), 601–603 (2000).
   Google Scholar
• Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson’s disease and sleepiness: an integral part of PD. Neurology58, 1019–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Beove BF, Silber MH, Ferman TJ et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord.16, 622–630 (2001).
   Google Scholar
• Adler CH, Thorpy MJ. Sleep issues in Parkinson’s disease. Neurology64(Suppl. 3), S12–S20 (2005).
   PubMed Web of Science ®Google Scholar
• Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann. Neurol.34, 710–714 (1993).
   PubMed Web of Science ®Google Scholar
• Ozekmekci S, Apaydin H, Kilic E. Clinical features of 35 patients with Parkinson’s disease displaying REM behavior disorder. Clin. Neurol. Neurosurg.107(4), 306–309 (2005).
   Google Scholar
• Morrison AR. The pathophysiology of REM-sleep behavior disorder. Sleep21, 446–449 (1998).
   Google Scholar
• Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch. Neurol.59(3), 421–424 (2002).
   PubMed Web of Science ®Google Scholar
• Chesson AL Jr, Wise M, Davila D et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep.22(7), 961–968 (1999).
   PubMed Web of Science ®Google Scholar
• Nomura T, Inoue Y, Nakashima K. Clinical characteristics of restless legs syndrome in patients with Parkinson’s disease. J. Neurol. Sci.250(1–2), 39–44. (2006).
   PubMed Web of Science ®Google Scholar
• Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat. Disord.11(1), 49–55 (2005).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Friedman H. Fatigue in Parkinson’s disease: a nine-year follow-up. Mov. Disord. (2001) 16(6), 1120–1122.
   PubMed Web of Science ®Google Scholar
• Friedman J, Friedman H. Fatigue in Parkinson’s disease. Neurology43(10), 2016–2018 (1993).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Depression and Parkinson’s disease: a review. Am. J. Psychiatry149, 443–454 (1992).
   PubMed Web of Science ®Google Scholar
• Ehmann TS, Beninger RJ, Gawal MJ, Riopelle RJ. Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J. Geriatr. Psychiatry Neurol.3(1), 3–9 (1990).
   PubMedGoogle Scholar
• Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry49, 381–389 (1986).
   PubMed Web of Science ®Google Scholar
• Celesia GC, Wanamaker WM. Psychiatric disturbances in Parkinson’s disease. Dis. Nerv. Syst.33, 577–583 (1972).
   PubMedGoogle Scholar
• Mayeux R, Stern Y, Williams JBW, Cote L, Frantz A, Dyrenfurth I. Clinical and biochemical features of depression in Parkinson’s disease. Am. J. Psychiatry143, 756–759 (1986).
   PubMed Web of Science ®Google Scholar
• Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ. The relationship of serotonin to depression in Parkinson’s disease. Mov. Disord.3, 237–244 (1988).
   PubMed Web of Science ®Google Scholar
• Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa. Acta Neurol. Scand.52, 210–219 (1980).
   Google Scholar
• Laitenen L. Desipramine in treatment of Parkinson’s disease. Acta Neurol. Scand.45, 109–113 (1969).
   Google Scholar
• Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurology34, 1092–1094 (1984).
   PubMed Web of Science ®Google Scholar
• Jansen-Steur ENH. Increase of Parkinson disability after fluoxetine medication. Neurology43, 211–213 (1993).
   Google Scholar
• Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G et al. Parkinsonism exacerbated by paroxetine. Neurology44, 2406 (1994).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov. Disord.12, 756–759 (1997).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson’s disease: an open-label, flexible-dosage study. J. Neuropsychiatry Clin. Neurosci.18(3), 377–383 (2006).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Morales KH, Moberg PJ et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov. Disord.20(9), 1161–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Sternbach H. The serotonin syndrome. Am. J. Psychiatry148, 705–713 (1991).
   PubMed Web of Science ®Google Scholar
• Nirenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin. Pharmacol. Ther.53(1), 84–88 (1993).
   Google Scholar
• Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia42, 760–763 (1987).
   Google Scholar
• Corkeron MA. Serotonin syndrome – a potentially fatal complication of antidepressant therapy. Med. J. Austral.163, 481–482 (1995).
   PubMed Web of Science ®Google Scholar
• Waters CH. Fluoxetine and selegiline – lack of significant interaction. Can. J. Neurol.21, 259–261 (1994).
   PubMed Web of Science ®Google Scholar
• Richard IH, Kurlan R, Tanner C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology48, 1070–1077 (1997).
   PubMed Web of Science ®Google Scholar
• Richard IH. Anxiety disorders in Parkinson’s disease. Adv. Neurol.96, 42–55 (2005).
   PubMedGoogle Scholar
• Witjas T, Kaphan E, Azulay JP et al. Nonmotor flucutuations in Parkinson’s disease: frequent and disabling. Neurology59, 408–413 (2002).
   PubMed Web of Science ®Google Scholar
• Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex16, 916–928 (2006).
   PubMed Web of Science ®Google Scholar
• Levy ML, Cummings JL, Fairbanks LA et al. Apathy is not depression. J. Neuropsychiatry10, 314–319 (1998).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mayberg SE Preziosi TJ et al. Reliability, validity and clinical correlates of apathy in Parkinson’s disease. J. Neuropsychiatry4, 134–139 (1992).
   PubMed Web of Science ®Google Scholar
• Pluck GC, Brown RG. Apathy in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry73, 636–642 (2002).
   PubMed Web of Science ®Google Scholar
• Padala PR, Petty F, Bhatia SC. Methylphenidate may treat apathy independend of depression. Ann. Pharmacother.39, 1947–1949 (2005).
   Google Scholar
• Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol.2(4), 229–237 (2003).
   PubMed Web of Science ®Google Scholar
• Aarsland D, AndersenK, Larsen J et al. Prevalence and characteristics of dementia in Parkinson’s disease: an 8-year prospective study. Arch. Neurol.60, 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• Peran P, Rascol O, Demonet JF et al. Deficit of verb generation in nondemented patients with Parkinson’s disease. Mov. Disord.18, 150–156 (2003).
   PubMed Web of Science ®Google Scholar
• Agid Y, Ruberg M, Dubois B et al. Parkinson’s disease and dementia. Clin. Neuropharm.9, S22–S36 (1986).
   Google Scholar
• Parashos SA, Maraganore DM, O’Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin. Proc.77(9), 918–925 (2002).
   Google Scholar
• McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology47(5), 1113–1124 (1996).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donopezil for dementia in Parkinson’s disease: a randomized, double-blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76(7), 934–939 (2005).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351(24), 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M et al. EXPRESS Investigators. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov. Disord.21(4), 456–461 (2006).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76(7), 934–999 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry18(10), 937–941 (2003).
   PubMed Web of Science ®Google Scholar
• Thanvi BR, Lo TC, Harsh DP. Psychosis in Parkinson’s disease. Postgrad. Med. J.81(960), 644–646 (2005).
   PubMed Web of Science ®Google Scholar
• Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson’s disease: Structured review and meta-analysis. Eur. Neuropsychopharmacol.17(3), 165–171 (2006).
   Google Scholar
• Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for parkinson’s disease psychosis. Clin. Neuropharmacol.29(6), 331–337 (2006).
   PubMed Web of Science ®Google Scholar
• Waseem S, Gwinn-Hardy K. Pain in Parkinson’s disease: common yet seldom recognized symptom is treatable. Postgrad. Med.110, 33–40 (2001).
   Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Levy M et al. Pain in Parkinson’s disease. Mov. Disord.1(1), 45–49 (1986).
   PubMedGoogle Scholar
• Quinn NP, Koller WC, Lang AE et al. Painful Parkinson’s disease. Lancet1, 1366–1369 (1996).
   Google Scholar
• Pacchetti C, Albani G, Martignoni E et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov. Disord.10(3), 333–336 (1995).
   PubMed Web of Science ®Google Scholar
• Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry62, 436–446 (1997).
   PubMed Web of Science ®Google Scholar
• Double KL, Rowe DB, Hayes M et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch. Neurol.60, 545–549 (2003).
   PubMed Web of Science ®Google Scholar
• Doty RL, Deems DA, Stellar S. Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology38(8), 1237–1244 (1988).
   PubMed Web of Science ®Google Scholar
• Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J. Chronic Dis.28, 493–497 (1975).
   PubMedGoogle Scholar
• Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry55, 138–142 (1992).
   PubMed Web of Science ®Google Scholar
• Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECH, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann. Neurol.56, 173–181 (2004).
   PubMed Web of Science ®Google Scholar
• Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson’s disease. Vision Res.45(10), 1285–1296 (2005).
   PubMed Web of Science ®Google Scholar
• Lee AC, Harris JP. Problems with perception of space in Parkinson’s disease. Neuroophthalmology22, 1–15 (1999).
   Web of Science ®Google Scholar